NCT06852053 Application to Predict Neonatal Apnea With Bradycardia
| NCT ID | NCT06852053 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Alabama at Birmingham |
| Condition | Apnea Neonatal |
| Study Type | INTERVENTIONAL |
| Enrollment | 25 participants |
| Start Date | 2026-09-29 |
| Primary Completion | 2027-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 25 participants in total. It began in 2026-09-29 with a primary completion date of 2027-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This purpose of this study is to reduce or stop apneas and bradycardias in pre-term infants, before they occur using gentle stimulation.
Eligibility Criteria
Inclusion Criteria: * Documented episodes of apnea with bradycardia over the previous 24 hours. * Off ventilatory support/NCPAP for \> 48 hours prior to study entry * Gestational age \< 32 0/7 weeks' gestation at birth * Parents/legal guardians have provided consent for enrollment Exclusion Criteria: * a major malformation or a neuromuscular condition that affects respiration or causes apnea, or terminal illness or decision to withhold or limit support.
Contact & Investigator
Colm P. Travers Associate Professor of Pediatrics, M.D.
PRINCIPAL INVESTIGATOR
University of Alabama at Birmingham
Frequently Asked Questions
Who can join the NCT06852053 clinical trial?
This trial is open to participants of all sexes, aged 22 Weeks or older, up to 32 Weeks, studying Apnea Neonatal. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06852053 currently recruiting?
Yes, NCT06852053 is actively recruiting participants. Contact the research team at rlbenz@uabmc.edu for enrollment information.
Where is the NCT06852053 trial being conducted?
This trial is being conducted at Birmingham, United States.
Who is sponsoring the NCT06852053 clinical trial?
NCT06852053 is sponsored by University of Alabama at Birmingham. The principal investigator is Colm P. Travers Associate Professor of Pediatrics, M.D. at University of Alabama at Birmingham. The trial plans to enroll 25 participants.